WEDNESDAY, JANUARY 13
Antibodies as Drugs for COVID-19 (7am Denver/Mountain Time Start)
*David P. Humphreys, UCB Pharma, UK
*Esther Breij, Genmab, Netherlands
Bo Barnhart, Abcellera Biologics Inc., Canada
Combating COVID-19: Identifying a Potential Drug Candidate for Human Testing in 90 Days
Christos Kyratsous, Regeneron Pharmaceuticals Inc, USA
Rapid Selection, Characterization and Clinical Development of Fully-Human Antibodies Against Emerging Infectious Diseases
Davide Corti, Vir Biotechnology, Switzerland
Cross-Neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody
X. Sunney Xie, Peking University, China
COVID-19 Neutralizing Antibodies Screened by Single Cell Genomics
Linqi Zhang, Tsinghua University, China
Human Neutralizing Antibodies Elicited by SARS-CoV-2 Infection
Xavier Saelens, Ghent University, Belgium
When Size Matters: A Broadly Neutralizing Single Domain Antibody to Prevent and Treat COVID-19
Michael Stumpp, Molecular Partners, Switzerland
Highly Potent Anti-SARS-CoV-2 Multivalent DARPin in Therapeutic Candidates
Michael G. Ison, Northwestern/Celltrion, Inc., USA
Therapeutic Effect of Regdanvimab (CT-P59) in Patients with Mild to Moderate Symptoms of SARS-CoV-2 Infection
Natalia Freund, 275.00
Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors

Poster Session (11am Denver/Mountain Time Start)

THURSDAY, JANUARY 14
Vaccines as Drugs for COVID-19 (7am Denver/Mountain Time Start)
*David P. Humphreys, UCB Pharma, UK
*Pierre Bruhns, Institut Pasteur, France
Liise-anne Pirofski, Albert Einstein College of Medicine and Montefiore Medical Center, USA
The Challenges of a New Vaccine for a New Disease
Paul F. McKay, Imperial College, UK
Development of a Self-Amplifying RNA Vaccine for COVID-19
Andrea Carfi, Moderna, USA
Potent Vaccine Efficacy from mRNA-1273 Expressing SARS-CoV-2 Spike Protein Stabilized in the Prefusion Conformation
Alexander Muik, BioNTech, Germany
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Trevor RF Smith, Inovio, USA
Development of INO-4800, a DNA Vaccine for COVID-19

Sarah Catherine Gilbert, University of Oxford, UK
Development of ChAdOx1 nCoV-19 (AZD1222); Creating a Vaccine in a Pandemic Setting
Hanneke Schuitemaker, Janssen Vaccines & Prevention B.V., Netherlands
Janssen’s Efforts in the Development of an Ad26 Based COVID-19 Vaccine
Susanne Rauch, CureVac GmbH, Germany
Development of the mRNA based SARS-CoV-2 Vaccine CVnCoV
Neeltje van Doremalen, 275.00
Intranasal Vaccination with ChAdOx1 nCoV-19 Results in Reduced Nasal Shedding and Lack of Lower Respiratory Tract Infection in SARS-CoV-2 Hamsters and Rhesus macaques

Networking Lounge (10am Denver/Mountain Time Start)